Stock Events

Stock Events

Hemogenyx Pharmaceuticals 

€0.013000
36
-€4.99-99.74% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
24
52W Low
0.013
Volume
-
Avg. Volume
0
Mkt Cap
78,533
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-11.28MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5HU.STU. It's not an investment recommendation.
Tesla
4
TSLA
National Grid
4
NG.LSE
Legal & General Group
3
LGEN.LSE
Apple
2
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology Hemogenyx could utilize in developing its therapies for blood-related diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is pioneering RNAi therapeutics, a novel form of treatment that could overlap with Hemogenyx's target diseases.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for blood disorders, directly competing with Hemogenyx's focus area.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in the treatment of blood diseases, including cell therapies, which puts it in competition with Hemogenyx.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which involve blood disorders that could be targeted by Hemogenyx's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in creating new therapies for genetic diseases, including blood disorders, competing with Hemogenyx's research focus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse portfolio in biotechnology, including treatments for blood disorders, making it a competitor to Hemogenyx.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its extensive research and development in various therapeutic areas, including blood disorders, competes with Hemogenyx's niche focus.

About

HEMOGENYX PHARMA PLC
Show more...
CEO
Vladislav Sandler
Employees
16
Country
United Kingdom
ISIN
GB00BYX3WZ24
WKN
000A40WGA

Listings

STU
DE
5HU0.STU
STU
DE
5HU.STU
F
DE
5HU0.F
LSE
GB
HEMO.LSE

0 Comments

Share your thoughts

FAQ

What is Hemogenyx Pharmaceuticals stock price today?▼
The current price of 5HU.STU is €0.01 EUR — it has decreased by -99.74% in the past 24 hours. Watch Hemogenyx Pharmaceuticals stock price performance more closely on the chart.
What is Hemogenyx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Hemogenyx Pharmaceuticals stocks are traded under the ticker 5HU.STU.
Is Hemogenyx Pharmaceuticals stock price growing?▼
5HU.STU stock has fallen by -7.94% compared to the previous week, the month change is a -20% fall, over the last year Hemogenyx Pharmaceuticals has showed a -28.4% decrease.
What is Hemogenyx Pharmaceuticals market cap?▼
Today Hemogenyx Pharmaceuticals has the market capitalization of 78,533
What is Hemogenyx Pharmaceuticals revenue for the last year?▼
Hemogenyx Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Hemogenyx Pharmaceuticals net income for the last year?▼
5HU.STU net income for the last year is -11.28M EUR.
How many employees does Hemogenyx Pharmaceuticals have?▼
As of September 06, 2026, the company has 16 employees.
In which sector is Hemogenyx Pharmaceuticals located?▼
Hemogenyx Pharmaceuticals operates in the Health & Wellness sector.
When did Hemogenyx Pharmaceuticals complete a stock split?▼
Hemogenyx Pharmaceuticals has not had any recent stock splits.
Where is Hemogenyx Pharmaceuticals headquartered?▼
Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.